Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aptiv Solutions Growing: Opens New Office in North Carolina

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
New office is located at 4505 Emperor Boulevard in the Imperial Center.

Aptiv Solutions has announced the opening of a new office in Durham, North Carolina.

The new office is located at 4505 Emperor Boulevard in the Imperial Center, an elite business park convenient to Raleigh, Durham, Chapel Hill, Cary and Research Triangle Park.

Aptiv Solutions and its subsidiary Trio Clinical Resourcing previously resided in separate offices in Raleigh and Morrisville.

The decision to combine the offices arose from growth of staff and the desire to co-locate the North Carolina based teams.

The new office includes team members from the clinical, data management and biostatistics, regulatory, translational sciences, medical consulting, pharmacovigilance, quality assurance, proposal development, information technology, finance, business development and human resources teams for Aptiv Solutions and the Trio Clinical Resourcing team.

“We are delighted to have our Aptiv Solutions and Trio Clinical Resourcing teams all under one roof in the new Durham, North Carolina office,” commented Pat Donnelly, Chairman and CEO of Aptiv Solutions.

Donnelly continued, “We continue to experience rapid growth as we expand to meet the expansion in our client base. Our new office not only accommodates our current staff levels, but allows for the anticipated future growth of our North Carolina operations”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aptiv Solutions to be Acquired by ICON
Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide.
Monday, March 31, 2014
Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.
Friday, May 24, 2013
Scientific News
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!